Search

Your search keyword '"Chitty, Lyn S."' showing total 922 results
Start Over Author "Chitty, Lyn S."
922 results on '"Chitty, Lyn S."'

205. Evaluation of Array Comparative genomic Hybridisation in prenatal diagnosis of fetal anomalies: a multicentre cohort study with cost analysis and assessment of patient, health professional and commissioner preferences for array comparative genomic hybridisation

Author

Robson, Stephen C, primary, Chitty, Lyn S, additional, Morris, Stephen, additional, Verhoef, Talitha, additional, Ambler, Gareth, additional, Wellesley, Diana G, additional, Graham, Ruth, additional, Leader, Claire, additional, Fisher, Jane, additional, and Crolla, John A, additional

Published
2017
Full Text
View/download PDF

207. Uptake, Outcomes, and Costs of Implementing Non-invasive Prenatal Testing for Down Syndrome Into NHS Maternity Care: Prospective Cohort Study in Eight Diverse Maternity Units

Author

Chitty, Lyn S., primary, Wright, David, additional, Hill, Melissa, additional, Verhoef, Talitha I., additional, Daley, Rebecca, additional, Lewis, Celine, additional, Mason, Sarah, additional, McKay, Fiona, additional, Jenkins, Lucy, additional, Howarth, Abigail, additional, Cameron, Louise, additional, McEwan, Alec, additional, Fisher, Jane, additional, Kroese, Mark, additional, and Morris, Stephen, additional

Published
2016
Full Text
View/download PDF

210. Mutations in Citron Kinase Cause Recessive Microlissencephaly with Multinucleated Neurons

Author

Harding, Brian N., primary, Moccia, Amanda, additional, Drunat, Séverine, additional, Soukarieh, Omar, additional, Tubeuf, Hélène, additional, Chitty, Lyn S., additional, Verloes, Alain, additional, Gressens, Pierre, additional, El Ghouzzi, Vincent, additional, Joriot, Sylvie, additional, Di Cunto, Ferdinando, additional, Martins, Alexandra, additional, Passemard, Sandrine, additional, and Bielas, Stephanie L., additional

Published
2016
Full Text
View/download PDF

211. Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down’s syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units

Author

Chitty, Lyn S, primary, Wright, David, additional, Hill, Melissa, additional, Verhoef, Talitha I, additional, Daley, Rebecca, additional, Lewis, Celine, additional, Mason, Sarah, additional, McKay, Fiona, additional, Jenkins, Lucy, additional, Howarth, Abigail, additional, Cameron, Louise, additional, McEwan, Alec, additional, Fisher, Jane, additional, Kroese, Mark, additional, and Morris, Stephen, additional

Published
2016
Full Text
View/download PDF

218. Noninvasive Prenatal Diagnosis for Cystic Fibrosis

Author

Hill, Melissa, primary, Twiss, Philip, additional, Verhoef, Talitha I., additional, Drury, Suzanne, additional, McKay, Fiona, additional, Mason, Sarah, additional, Jenkins, Lucy, additional, Morris, Stephen, additional, and Chitty, Lyn S., additional

Published
2016
Full Text
View/download PDF

220. Non-invasive prenatal testing for aneuploidy and beyond : challenges of responsible innovation in prenatal screening

Author

Dondorp, Wybo, de Wert, Guido, Bombard, Yvonne, Bianchi, Diana W., Bergmann, Carsten, Borry, Pascal, Chitty, Lyn S., Fellmann, Florence, Forzano, Francesca, Hall, Alison, Henneman, Lidewij, Howard, Heidi C., Lucassen, Anneke, Ormond, Kelly, Peterlin, Borut, Radojkovic, Dragica, Rogowski, Wolf, Soller, Maria, Tibben, Aad, Tranebjaerg, Lisbeth, van El, Carla G., Cornel, Martina C., Dondorp, Wybo, de Wert, Guido, Bombard, Yvonne, Bianchi, Diana W., Bergmann, Carsten, Borry, Pascal, Chitty, Lyn S., Fellmann, Florence, Forzano, Francesca, Hall, Alison, Henneman, Lidewij, Howard, Heidi C., Lucassen, Anneke, Ormond, Kelly, Peterlin, Borut, Radojkovic, Dragica, Rogowski, Wolf, Soller, Maria, Tibben, Aad, Tranebjaerg, Lisbeth, van El, Carla G., and Cornel, Martina C.

Abstract

This paper contains a joint ESHG/ASHG position document with recommendations regarding responsible innovation in prenatal screening with non-invasive prenatal testing (NIPT). By virtue of its greater accuracy and safety with respect to prenatal screening for common autosomal aneuploidies, NIPT has the potential of helping the practice better achieve its aim of facilitating autonomous reproductive choices, provided that balanced pretest information and non-directive counseling are available as part of the screening offer. Depending on the health-care setting, different scenarios for NIPT-based screening for common autosomal aneuploidies are possible. The trade-offs involved in these scenarios should be assessed in light of the aim of screening, the balance of benefits and burdens for pregnant women and their partners and considerations of cost-effectiveness and justice. With improving screening technologies and decreasing costs of sequencing and analysis, it will become possible in the near future to significantly expand the scope of prenatal screening beyond common autosomal aneuploidies. Commercial providers have already begun expanding their tests to include sex-chromosomal abnormalities and microdeletions. However, multiple false positives may undermine the main achievement of NIPT in the context of prenatal screening: the significant reduction of the invasive testing rate. This document argues for a cautious expansion of the scope of prenatal screening to serious congenital and childhood disorders, only following sound validation studies and a comprehensive evaluation of all relevant aspects. A further core message of this document is that in countries where prenatal screening is offered as a public health programme, governments and public health authorities should adopt an active role to ensure the responsible innovation of prenatal screening on the basis of ethical principles. Crucial elements are the quality of the screening process as a whole (including non

Published
2015
Full Text
View/download PDF

221. Non-invasive prenatal testing for aneuploidy and beyond:challenges of responsible innovation in prenatal screening

Author

Dondorp, Wybo, de Wert, Guido, Bombard, Yvonne, Bianchi, Diana W, Bergmann, Carsten, Borry, Pascal, Chitty, Lyn S, Fellmann, Florence, Forzano, Francesca, Hall, Alison, Henneman, Lidewij, Howard, Heidi C, Lucassen, Anneke, Ormond, Kelly, Peterlin, Borut, Radojkovic, Dragica, Rogowski, Wolf, Soller, Maria, Tibben, Aad, Tranebjærg, Lisbeth, van El, Carla G, Cornel, Martina C, Dondorp, Wybo, de Wert, Guido, Bombard, Yvonne, Bianchi, Diana W, Bergmann, Carsten, Borry, Pascal, Chitty, Lyn S, Fellmann, Florence, Forzano, Francesca, Hall, Alison, Henneman, Lidewij, Howard, Heidi C, Lucassen, Anneke, Ormond, Kelly, Peterlin, Borut, Radojkovic, Dragica, Rogowski, Wolf, Soller, Maria, Tibben, Aad, Tranebjærg, Lisbeth, van El, Carla G, and Cornel, Martina C

Abstract

This paper contains a joint ESHG/ASHG position document with recommendations regarding responsible innovation in prenatal screening with non-invasive prenatal testing (NIPT). By virtue of its greater accuracy and safety with respect to prenatal screening for common autosomal aneuploidies, NIPT has the potential of helping the practice better achieve its aim of facilitating autonomous reproductive choices, provided that balanced pretest information and non-directive counseling are available as part of the screening offer. Depending on the health-care setting, different scenarios for NIPT-based screening for common autosomal aneuploidies are possible. The trade-offs involved in these scenarios should be assessed in light of the aim of screening, the balance of benefits and burdens for pregnant women and their partners and considerations of cost-effectiveness and justice. With improving screening technologies and decreasing costs of sequencing and analysis, it will become possible in the near future to significantly expand the scope of prenatal screening beyond common autosomal aneuploidies. Commercial providers have already begun expanding their tests to include sex-chromosomal abnormalities and microdeletions. However, multiple false positives may undermine the main achievement of NIPT in the context of prenatal screening: the significant reduction of the invasive testing rate. This document argues for a cautious expansion of the scope of prenatal screening to serious congenital and childhood disorders, only following sound validation studies and a comprehensive evaluation of all relevant aspects. A further core message of this document is that in countries where prenatal screening is offered as a public health programme, governments and public health authorities should adopt an active role to ensure the responsible innovation of prenatal screening on the basis of ethical principles. Crucial elements are the quality of the screening process as a whole (including n

Published
2015

222. Non-invasive prenatal testing for aneuploidy and beyond:challenges of responsible innovation in prenatal screening. Summary and recommendations

Author

Dondorp, Wybo, de Wert, Guido, Bombard, Yvonne, Bianchi, Diana W, Bergmann, Carsten, Borry, Pascal, Chitty, Lyn S, Fellmann, Florence, Forzano, Francesca, Hall, Alison, Henneman, Lidewij, Howard, Heidi C, Lucassen, Anneke, Ormond, Kelly, Peterlin, Borut, Radojkovic, Dragica, Rogowski, Wolf, Soller, Maria, Tibben, Aad, Tranebjærg, Lisbeth, van El, Carla G, Cornel, Martina C, Dondorp, Wybo, de Wert, Guido, Bombard, Yvonne, Bianchi, Diana W, Bergmann, Carsten, Borry, Pascal, Chitty, Lyn S, Fellmann, Florence, Forzano, Francesca, Hall, Alison, Henneman, Lidewij, Howard, Heidi C, Lucassen, Anneke, Ormond, Kelly, Peterlin, Borut, Radojkovic, Dragica, Rogowski, Wolf, Soller, Maria, Tibben, Aad, Tranebjærg, Lisbeth, van El, Carla G, and Cornel, Martina C

Published
2015

223. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Summary and recommendations.

Author

Dondorp, Wybo, de Wert, Guido, Bombard, Yvonne, Bianchi, Diana W, Bergmann, Carsten, Borry, Pascal, Chitty, Lyn S, Fellmann, Florence, Forzano, Francesca, Hall, Alison, Henneman, Lidewij, Howard, Heidi C, Lucassen, Anneke, Ormond, Kelly, Peterlin, Borut, Radojkovic, Dragica, Rogowski, Wolf, Soller, Maria, Tibben, Aad, Tranebjærg, Lisbeth, van El, Carla G, Cornel, Martina C, Dondorp, Wybo, de Wert, Guido, Bombard, Yvonne, Bianchi, Diana W, Bergmann, Carsten, Borry, Pascal, Chitty, Lyn S, Fellmann, Florence, Forzano, Francesca, Hall, Alison, Henneman, Lidewij, Howard, Heidi C, Lucassen, Anneke, Ormond, Kelly, Peterlin, Borut, Radojkovic, Dragica, Rogowski, Wolf, Soller, Maria, Tibben, Aad, Tranebjærg, Lisbeth, van El, Carla G, and Cornel, Martina C

Published
2015

225. Preferences for prenatal tests for Down syndrome: an international comparison of the views of pregnant women and health professionals

Author

Hill, Melissa, primary, Johnson, Jo-Ann, additional, Langlois, Sylvie, additional, Lee, Hyun, additional, Winsor, Stephanie, additional, Dineley, Brigid, additional, Horniachek, Marisa, additional, Lalatta, Faustina, additional, Ronzoni, Luisa, additional, Barrett, Angela N, additional, Advani, Henna V, additional, Choolani, Mahesh, additional, Rabinowitz, Ron, additional, Pajkrt, Eva, additional, van Schendel, Rachèl V, additional, Henneman, Lidewij, additional, Rommers, Wieke, additional, Bilardo, Caterina M, additional, Rendeiro, Paula, additional, Ribeiro, Maria João, additional, Rocha, José, additional, Bay Lund, Ida Charlotte, additional, Petersen, Olav B, additional, Becher, Naja, additional, Vogel, Ida, additional, Stefánsdottir, Vigdis, additional, Ingvarsdottir, Sigrun, additional, Gottfredsdottir, Helga, additional, Morris, Stephen, additional, and Chitty, Lyn S, additional

Published
2015
Full Text
View/download PDF

226. Variability of ffDNA in maternal plasma does not prevent correct classification of trisomy 21 using MeDIP‐qPCR methodology

Author

Kyriakou, Skevi, Kypri, Elena, Spyrou, Christiana, Tsaliki, Evdokia, Velissariou, Voula, Papageorgiou, Elisavet A., Patsalis, Philippos C., Chitty, Lyn S., and Bianchi, Diana W.

Abstract

ID: 1199 In: PRENATAL DIAGNOSIS volume 33 issue 7 page 650. Summary: ABSTRACT Objective The goal of this study is to evaluate the amount of free fetal DNA (ffDNA), total DNA, and ‘fetal fraction’ found in maternal plasma and whether these influence the enrichment ratios of differentially methylated regions (DMRs) and the correct classification of trisomy 21 using the methylated DNA immunoprecipitation‐quantitative polymerase chain reaction (MeDIP‐qPCR)‐based noninvasive prenatal diagnostic methodology applied in peripheral blood. Methods Absolute quantification of ffDNA using DYS14 and total DNA using β‐globin was applied in 83 maternal plasma samples. The quantification values for all 83 samples were correlated with the enrichment ratios of all seven DMRs and D‐values that were obtained from the diagnostic formula of MeDIP‐qPCR method. Results Our analysis concluded that trisomy 21 samples had significantly higher ffDNA and total DNA levels compared with those of normal samples. Enrichment ratios of the majority of DMRs studied exhibited no association with ffDNA, total DNA, and ‘fetal fraction’, and only a small portion of DMRs exhibited moderate association. Correlation studies of ffDNA, total DNA, and fetal fraction with the diagnostic D‐value showed weak to no association but without affecting the classification of trisomy 21. Conclusion Overall, the variability of ffDNA and total DNA among maternal samples does not affect the correct trisomy 21 classification using MeDIP‐qPCR methodology applied in peripheral blood. © 2013 John Wiley & Sons, Ltd. .

Published
2013

227. Clinical, social and ethical issues associated with non-invasive prenatal testing for aneuploidy.

Author

Griffin, Blanche, Edwards, Samantha, Chitty, Lyn S., and Lewis, Celine

Subjects
PRENATAL diagnosis, ANEUPLOIDY, FALSE positive error, DOWN syndrome, DECISION making, MEDICAL personnel, ETHICS
Abstract

Non-invasive prenatal testing (NIPT), based on analysis of cell-free foetal DNA, is rapidly becoming a preferred method to screen for chromosomal aneuploidy with the technology now available in over 90 countries. This review provides an up-to-date discussion of the key clinical, social and ethical implications associated with this revolutionary technology. Stakeholders are positive about a test that is highly accurate, safe, can be perfomed early in pregnancy, identifies affected pregnancies that might otherwise have been missed and reduces the need for invasive testing. Nevertheless, professional societies currently recommend it as an advanced screening test due to the low false positive rate (FPR). Despite the practical and psychological benefits, a number of concerns have been raised which warrant attention. These include the potential for routinisation of testing and subsequent impact on informed decision-making, an "easy" blood test inadvertently contributing to women feeling pressured to take the test, fears NIPT will lead to less tolerance and support for those living with Down syndrome and the heightened expectation of having "perfect babies". These issues can be addressed to some extent through clinician education, patient information and establishing national and international consensus in the development of comprehensive and regularly updated guidelines. As the number of conditions we are able to test for non-invasively expands it will be increasingly important to ensure pre-test counselling can be delivered effectively supported by knowledgeable healthcare professionals. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

228. Stakeholder views and attitudes towards prenatal and postnatal transplantation of fetal mesenchymal stem cells to treat Osteogenesis Imperfecta

Author

Hill, Melissa, Lewis, Celine, Riddington, Megan, Crowe, Belinda, DeVile, Catherine, David, Anna L., Semler, Oliver, Westgren, Magnus, Götherström, Cecilia, and Chitty, Lyn S

Abstract

The Boost Brittle Bones Before Birth (BOOSTB4) clinical trial is investigating the safety and efficacy of transplanting fetal derived mesenchymal stromal cells (MSCs) prenatally and/or in early postnatal life to treat severe Osteogenesis Imperfecta (OI). This study aimed to explore stakeholder views to understand perceived benefits or concerns, identify ethical issues and establish protocols for support and counselling. Semi-structured qualitative interviews were conducted with three groups; 1. Adults affected with OI, with and without children, and parents of children affected with OI; 2. Health professionals who work with patients with OI; 3. Patient advocates from relevant patient support groups. Interviews were digitally recorded, transcribed verbatim and analysed using thematic analysis. Interviews with 56 participants revealed generally positive views towards using fetal MSC transplantation to treat OI. Early treatment was considered advantageous for preventing fractures and reducing severity and could bring psychological benefits for parents. Common concerns were procedure safety, short/long-term side effects and whether transplantation would be effective. Difficulties inherent in decision-making were frequently discussed, as treatment efficacy is unknown and, by necessity, parents will make decisions at a time when they are vulnerable. Support needs may differ where there is a family history of OI compared to an unexpected diagnosis of OI. Explaining fetal MSC transplantation in a way that all parents can understand, clear expectation setting, psychological support and time for reflection during the decision-making process will be crucial to allow parents to make informed decisions about participation in the BOOSTB4 clinical trial.

Published
2019
Full Text
View/download PDF

230. Fetal forearm anomalies: prenatal diagnosis, associations and management strategy

Author

Pajkrt, Eva, Cicero, Simona, Griffin, David R., van Maarle, M. C., Chitty, Lyn S., Amsterdam Public Health, Amsterdam Reproduction & Development (AR&D), Obstetrics and Gynaecology, and Human Genetics

Abstract

Objective To determine the underlying associations in fetuses with forearm anomalies, and to derive a management strategy to improve prenatal diagnosis and parental counselling. Methods A retrospective review of fetal medicine unit records to identify all cases with an absent, short or abnormal radius and/or ulna. Cases with a generalised skeletal dysplasia were excluded. Fetal medicine, maternal, neonatal and, where appropriate, histopathological reports, were reviewed. Results Sixty-six cases were identified. Two were lost to follow-up and subsequently omitted. Chromosomal anomalies accounted for 19 cases (29.7%), genetic syndromes for 19 (29.7%) and isolated forearm defects for 15 cases (23%). A definitive postnatal diagnosis was made in 54 cases (84%). In 45 of the 64 (70%) cases, a correct prenatal diagnosis was made. Cases with bilateral lesions had a significantly higher association with aneuploidy and genetic syndromes, while those with a sonographically isolated unilateral forearm defect had a very low incidence of other underlying pathology. Conclusion Fetuses with bilateral forearm defects or those with unilateral lesions and other abnormalities detected prenatally have a high incidence of aneuploidy and genetic syndromes. Isolated, unilateral lesions usually have a good prognosis. A management strategy is presented to aid accurate prenatal diagnosis and parental counselling. (c) 2012 John Wiley & Sons, Ltd

Published
2012

237. Spina bifida

Author

Copp, Andrew J., primary, Adzick, N. Scott, additional, Chitty, Lyn S., additional, Fletcher, Jack M., additional, Holmbeck, Grayson N., additional, and Shaw, Gary M., additional

Published
2015
Full Text
View/download PDF

240. Diagnostic accuracy of post mortem MRI for abdominal abnormalities in foetuses and children

Author

Arthurs, Owen J., primary, Thayyil, Sudhin, additional, Owens, Catherine M., additional, Olsen, Oystein E., additional, Wade, Angie, additional, Addison, Shea, additional, Jones, Rod, additional, Norman, Wendy, additional, Scott, Rosemary J., additional, Robertson, Nicola J., additional, Taylor, Andrew M., additional, Chitty, Lyn S., additional, and Sebire, Neil J., additional

Published
2015
Full Text
View/download PDF

243. The Role of Sonographic Phenotyping in Delivering an Efficient Noninvasive Prenatal Diagnosis Service for FGFR3-Related Skeletal Dysplasias

Author

Mellis, Rhiannon, Chandler, Natalie, Jenkins, Lucy, and Chitty, Lyn S.

Abstract

(Abstracted from Prenat Diagn2020;40:785–791)Skeletal dysplasia can be difficult to diagnose on prenatal sonogram because of phenotypic overlap between conditions. Two of the more common skeletal dysplasias, achondroplasia and thanatophoric dysplasia (TD), occur because of mutations in the FGFR3gene.

Published
2020
Full Text
View/download PDF

248. Abnormal fetal head shape: aetiology and management

Author

Petersen, Olav Bjørn, David, Anna, Thomasson, Louise, and Chitty, Lyn S

Abstract

Background: Abnormal head shape is an uncommon finding on prenatal ultrasound, often associated with breech presentation, spinabifida, aneuploidy or secondary to oligohydramnios or fetal position. Other aetiologies are rarer and may be more difficult to define. Objective: To determine the aetiology and define management pathways for fetuses with an abnormal skull shape.Methods: Our FMU databases were searched to ascertain all fetuses with an abnormal skull shape. Sonographic findings, diagnosis and outcome were reviewed.Results: Of the 370 cases identified, 31.6% were associated with spinabifida (lemon-shaped), 18.4% with aneuploidy (mostly strawberry-shaped). 19.5% were dolicocephalic, most secondary to fetal position or oligohydramnios (see table). 13 had confirmed craniosynostosis, including thanatophoric dysplasia, Craniofrontonasal dysplasia, Aperts syndrome, Baller-Gerold syndrome, I-cell disease, Muenke craniosynostosis and two with an as yet undefined craniosynostosis syndrome. Overall, 16.5 % had an underlying genetic syndrome.Conclusions: Abnormal fetal head shape may be a normal variant, but is commonly associated with a wide variety of underlying pathologies. In view of the high incidence of genetic syndromes, in the absence of a clear diagnosis, referral to a tertiary centre and genetic input is advised as detection of subtle sonographic features may aid diagnosis, allowing for targeted molecular analysis. An algorithm for management will be proposed.

Published
2007

249. The natural history of prenatally diagnosed congenital cystic lung lesions: long-term follow-up of 119 cases.

Author

Cook, James, Chitty, Lyn S., De Coppi, Paolo, Ashworth, Michael, and Wallis, Colin

Subjects
PRENATAL diagnosis, CONGENITAL cystic adenomatoid malformation of lungs, LUNG abnormalities, COMPUTED tomography, LUNG diseases, AGE distribution, FETAL ultrasonic imaging, LONGITUDINAL method, PNEUMOTHORAX, PROGNOSIS, RESEARCH funding, RESPIRATORY infections, RESPIRATORY organ abnormalities, DISEASE complications
Abstract

Background: A paucity of evidence regarding the natural history of congenital pulmonary airway malformations (CPAMs) and pulmonary sequestration (PS) has resulted in a divergence in management strategy of asymptomatic cases.Methods: We describe the long-term clinical course of 119 children diagnosed with these lesions treated at Great Ormond Street Hospital (GOSH). Cases were identified via the GOSH patient database. Study entry required the identification of a cystic lung lesion on prenatal ultrasound and confirmation of CPAM/PS on postnatal CT imaging. Patients followed up for at least 5 years were included.Results: 51 (43%) patients were managed surgically; 8 (6.7%) as an emergency during the neonatal period, 6 (5.1%) electively due to concerning features on CT scan, 20 (17%) following medical advice, 1 (0.8%) following a severe respiratory infection and in 5 (4.2%) the indication was unclear. The indication in 11 (9.2%) was recurrent respiratory infection and median age at surgery was 1.6 years (range 0.4 to 4.6 years). No cases of malignancy were identified on histological examination of resected lesions. 68 (57%) patients were managed conservatively for a median period of 9.9 years (range 5.2 years to 18 years). Seven (10%) were discharged, one was followed-up elsewhere (1.5%) and eight (11%) were lost to follow-up. In four patients (5.9%), the lesion resolved spontaneously. 52 (76%) continue to be followed-up and remain asymptomatic.Conclusions: This is one of the largest case series documenting the natural history of CPAMs and PS following a prenatal diagnosis and demonstrates that conservative management is a reasonable option in selected cases. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

250. Evaluation of preferences of women and healthcare professionals in Singapore for implementation of noninvasive prenatal testing for Down syndrome.

Author

Barrett, Angela Natalie, Advani, Henna Vishal, Chitty, Lyn S., Lin Lin Su, Biswas, Arijit, Wei Ching Tan, Hill, Melissa, Choolani, Mahesh, Su, Lin Lin, and Tan, Wei Ching

Subjects
MEDICAL personnel, DNA, DEOXYRIBOSE, NUCLEIC acids, HUMAN chromosome 21
Abstract

Introduction: Invasive prenatal diagnosis (IPD) has long been used to prenatally diagnose Down syndrome (DS), but it is associated with a small risk of miscarriage. Noninvasive prenatal testing (NIPT) is a highly sensitive screening test using cell-free DNA in maternal blood for detection of DS without the risk of miscarriage, but it confers a small risk of false-positive and false-negative results. The implementation of these procedures into clinical practice requires an understanding of stakeholder preferences.Methods: A total of 69 health professionals (HPs) and 301 women took part in a discrete choice experiment (DCE) in which preferences for four prenatal test attributes - accuracy, time of results, risk of miscarriage and amount of information provided - were assessed. Conditional logit regression was used to analyse the data. Data on demographics and ranked preferences for test attributes was collected, and a direct choice question regarding NIPT, IPD or neither test was posed to participants.Results: The women showed a preference for test safety, whereas HPs prioritised test accuracy above all other attributes. When offered a direct choice of NIPT, IPD or neither test, women aged 35 years and older, those with previous miscarriage or who knew a child with DS were more likely to choose NIPT. Chinese women preferred NIPT, whereas Indian women preferred IPD.Conclusion: Our data highlights the need for patient-specific counselling, taking into account previous experiences and cultural factors. Since women and HPs prioritise different test attributes, it is essential that HPs recognise these differences in order to provide non-biased counselling. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results